With the writing apparently on the wall, PTC Therapeutics has called off its latest bid for FDA approval of its Duchenne muscular dystrophy (DMD) drug Translarna.  | Late Thursday, PTC revealed that ...

The passing of the One Big Beautiful Bill Act (OBBBA) in July 2025 brought forward deadlines for PV projects to receive U.S. tax credits introduced by previous legislation, and set new requirements to ...

Share Market Highlights - Find here all the highlights related to Sensex, Nifty, BSE, NSE, share prices and Indian stock ...

None ...

This trial tested the oral drug, branaplam, which lowered HTT but had serious safety problems, ultimately halting the trial. The results of a clinical trial, called VIBRANT-HD, investigating an oral ...

Despite a rise in trading volumes and income, PTC India Ltd faces profitability pressures and strategic uncertainties.

Applications are invited for recruitment of various teaching positions or career in KV NFR Rangiya Assam in 2026. Kendriya Vidyalaya (KV) is ...

Eli Lilly had $1.5 billion worth of pre-launch inventory of its experimental oral weight-loss drug ahead of an expected decision by the U.S. Food and Drug Administration in April, Reuters writes, ...

The firm originally submitted a new drug application seeking approval of the drug in 2016, which was rejected, and, in 2024, resubmitted an application.

This news release constitutes a “designated news release” for the purposes of the Company’s amended and restated ...

Three agents are approved, and more studies are underway ...

How attention cycles are reshaping trial, expectations, and retention. NEW YORK, NY, UNITED STATES, January 20, 2026 ...